HeroImageHome-m2
layer22mobile


GET THE
LATEST DATA

Sign up to receive
the latest about
XIENCE study
results as they
become available.

Sign up

You know XIENCE as the world's leading drug-eluting stent (DES), with an unparalleled safety record.1 The XIENCE safety heritage is now further strengthened with XIENCE Sierra’s exceptional acute performance. XIENCE Sierra continues to provide unparalleled safety1 along with enhanced deliverability for even the most complex percutaneous coronary interventions (PCI). Learn more about what XIENCE Sierra offers for even the most complex patients.

The Science Behind XIENCE Sierra

XIENCE Sierra features an ultra-low crossing profile* (0.0390″) that provides excellent deliverability. This newest generation XIENCE stent also offers expanded treatment options: 5.5 mm maximum post expansion.#

more

The Science Behind XIENCE Sierra

XIENCE Sierra features an ultra-low crossing profile (0.0390″) that provides excellent deliverability. This newest generation XIENCE stent also offers expanded treatment options: 5.5 mm maximum post expansion.#

more

XIENCE Safety For Complex PCI

Multiple recent XIENCE trial results, with endpoints ranging from 1 to 3 years,4-7 reveal excellent safety data on stent thrombosis (ST) in left main disease, diabetes and other complex conditions.

more

Xience Safety For Complex PCI

Multiple recent XIENCE trial results, with endpoints ranging from 1 to 3 years,4-7 reveal excellent safety data on stent thrombosis (ST) in left main disease, diabetes and other complex conditions.

more

Experts' and Patient's point of view

From comparative testing of XIENCE

In testing thromboresistance: “We are finding that circumferential [polymer coatings] behave much better. But by far the best is XIENCE.”

Renu Virmani, MD

Play video

From comparative testing of XIENCE

In testing thromboresistance: “We are finding that circumferential [polymer coatings] behave much better. But by far the best is XIENCE.”

Renu Virmani, MD

Play video

From comparative testing of XIENCE

In testing thromboresistance: “We are finding that circumferential [polymer coatings] behave much better. But by far the best is XIENCE.”

Renu Virmani, MD

Play video

From comparative testing of XIENCE

In testing thromboresistance: “We are finding that circumferential [polymer coatings] behave much better. But by far the best is XIENCE.”

Renu Virmani, MD

Play video

Get the Latest Data

Sign up to receive the latest about XIENCE study results, as they become available.

AP2944530-WBO Rev. C

 

# Maximum expansion for 3.5 mm and 4.0 mm

Test performed by and data on file at Abbott. XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5.

  1. XIENCE showed significant benefit compared to several DES and composite BMS in multiple large scale meta-analyses and other RCTs. Source: Palmerini, et al. The Lancet. 379:9824, 14-20 April 2012, pp. 1393-1402; Bangalore S, et al. Circ Cardiovasc Interv, Aug 6, 2013. doi: 10.1161/ circinterventions.113.000415.; Valgimigli, Effects of Cobalt-chromium Everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events. A patient-level meta analysis. EuroPCR 2014; Serruys, PW et al. RESOLUTE All Comers Trial, NEJM 2010. Published online June 16, 2010; Fajadet, J., et al. PLATINUM PLUS 30-day Poster, TCT 2012.
  2. Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.
  3. Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.
  4. Stone GW, et al. EXCEL Trial 3-year data. N Engl J Med. 2016;375:2223-2235. doi: 10.1056/NEJMoa1610227.
  5. Teeuwen K, et al. PRISON IV Trial 1-year data. JACC Cardiovasc Interv. 2016. doi: 10.1016/ j.jcin.2016.10.017.
  6. Kaul U. 2-Year TUXEDO Outcomes. TCT 2016.
  7. Lam, M. TWENTE Trial. Am Heart J.  2015;169:69-77. doi: 10.1016/j.ahj.2014.10.011.

 

 

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Disclaimer

The website you have requested is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit this website?